Results 141 to 150 of about 80,969 (285)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

The use of Reibergram in Cuban neuroimmunology

Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta, 2018
Cerebrospinal fluid (CSF) is an indispensable source of information for the diagnosis and progress of numerous neurological diseases. Reibergrams are diagrams in which the functionality of the blood-CSF barrier and the intrathecal synthesis of ...
Alvaro Pérez-Pérez
doaj  

The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to correlate potential links between the suspected adverse drug reaction (ADR) profile of licensed nonsteroidal androgen receptor antagonists (NSARA) with their unique chemical properties and known off‐target polypharmacology. Methods Physicochemical and polypharmacology data were curated from the Electronic Medicines Compendium ...
Simrit Dhillon, Albert A. Antolin, Alan M. Jones   +2 more
wiley   +1 more source

NLRP3-dependent lipid droplet formation contributes to posthemorrhagic hydrocephalus by increasing the permeability of the blood-cerebrospinal fluid barrier in the choroid plexus. [PDF]

Exp Mol Med, 2023
Zhang Z, Guo P, Liang L, Jila S, Ru X, Zhang Q, Chen J, Chen Z, Feng H, Chen Y.   +9 more
europepmc   +1 more source

Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Enzyme replacement therapy (ERT) for mucopolysaccharidosis II (MPS II) requires long‐term, weekly intravenous infusions often lasting over 3 h each time, which can burden paediatric patients and caregivers and negatively affect their quality of life and treatment compliance.
Kimitoshi Nakamura, Norio Sakai, Hideaki Hirai, Naoko Takasao, Ryo Ibaraki, Tatsuyoshi Yamamoto, Yuji Sato   +6 more
wiley   +1 more source

Age-dependent decline of copper clearance at the blood-cerebrospinal fluid barrier. [PDF]

Neurotoxicology, 2022
Liu LL, Du D, Zheng W, Zhang Y.
europepmc   +1 more source

Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy

BMEMat, EarlyView.
A ROS‐responsive, zwitterionic nanocage enables stable, intranasal siRNA delivery to glioblastoma, promoting deep tumor penetration via non‐degradative pathways and trigeminal nerve transport. This platform achieves durable gene silencing and tumor suppression, offering a non‐invasive, storage‐stable strategy for treating glioma and other neurological ...
Jingwen Xie, Jingxing Si, Xiaobei Deng, Jing Tan, Ruijie Zhu, Jizhou Qi, Gaoxia Ma, Bin Wang, Yi Wang, Yunzhou Guo, Yuping Chen, Shiqun Shao, Youqing Shen   +12 more
wiley   +1 more source

Central Nervous System Stimulants Limit Caffeine Transport at the Blood-Cerebrospinal Fluid Barrier. [PDF]

Int J Mol Sci, 2022
Ikeda-Murakami K, Tani N, Ikeda T, Aoki Y, Ishikawa T.   +4 more
europepmc   +1 more source

Letter. Dysfunction of the blood-cerebrospinal fluid barrier in bacterial meningitis [PDF]

Journal of Tropical Pediatrics, 1996
A, Dorta-Contreras, F A, Mieté
openaire   +2 more sources